Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,905 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.
Kiyohara E, Tanemura A, Sakura K, Nakajima T, Myoui A, Yamazaki N, Kiyohara Y, Katayama I, Fujimoto M, Kaneda Y. Kiyohara E, et al. Among authors: nakajima t. Cancer Immunol Immunother. 2022 Aug;71(8):2041-2049. doi: 10.1007/s00262-021-03122-z. Epub 2022 Jan 5. Cancer Immunol Immunother. 2022. PMID: 34984539 Free PMC article. Clinical Trial.
Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study.
Kiyohara E, Tanemura A, Nishioka M, Yamada M, Tanaka A, Yokomi A, Saito A, Sakura K, Nakajima T, Myoui A, Sakurai T, Kawakami Y, Kaneda Y, Katayama I. Kiyohara E, et al. Among authors: nakajima t. Cancer Immunol Immunother. 2020 Jun;69(6):1131-1140. doi: 10.1007/s00262-020-02509-8. Epub 2020 Feb 11. Cancer Immunol Immunother. 2020. PMID: 32047956 Free PMC article. Clinical Trial.
Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer.
Fujita K, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, Okihara K, Ukimura O, Miki T, Nakajima T, Kaneda Y, Nonomura N. Fujita K, et al. Among authors: nakajima t. Cancer Sci. 2020 May;111(5):1692-1698. doi: 10.1111/cas.14366. Epub 2020 Mar 19. Cancer Sci. 2020. PMID: 32112659 Free PMC article. Clinical Trial.
Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis.
Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, Inoue Y, McMurray DN, Sakatani M. Okada M, et al. Among authors: nakajima t. Clin Dev Immunol. 2011;2011:549281. doi: 10.1155/2011/549281. Epub 2011 Mar 7. Clin Dev Immunol. 2011. PMID: 21437226 Free PMC article.
Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models.
Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, Takamori Y, McMurray DN, De la Cruz EC, Tan EV, Abalos RM, Burgos JA, Saunderson P, Sakatani M. Kita Y, et al. Among authors: nakajima t. Hum Vaccin. 2011 Jan-Feb;7 Suppl:108-14. doi: 10.4161/hv.7.0.14571. Epub 2011 Jan 1. Hum Vaccin. 2011. PMID: 21263229
Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB.
Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Fukamizu R, Tsunai Y, Inoue R, Nakatani H, Namie Y, Yamada J, Takao K, Asai R, Asaki R, Matsumoto M, McMurray DN, Dela Cruz EC, Tan EV, Abalos RM, Burgos JA, Gelber R, Sakatani M. Okada M, et al. Among authors: nakajima t. Vaccine. 2007 Apr 20;25(16):2990-3. doi: 10.1016/j.vaccine.2007.01.014. Epub 2007 Jan 22. Vaccine. 2007. PMID: 17280753
5,905 results